PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29686117-10	2018	In people with CIS, glatiramer acetate and IFN-beta-1a subcutaneous 3 times per week are more effective than placebo in decreasing risk of conversion to MS. Cladribine, immunoglobulins, IFN-beta-1a 30 mug intramuscular weekly, IFN-beta-1b subcutaneous alternate day, and teriflunomide are probably more effective than placebo in decreasing risk of conversion to MS.	teriflunomide	271-284	interferon beta 1	Homo sapiens	43-51	
22622860-5	2012	The number of gadolinium-enhancing T1 (T1-Gd) lesions was reduced in both teriflunomide groups, with relative risk reductions (RRRs) of 84.6% (p = 0.0005) and 82.8% (p < 0.0001) for 7 and 14 mg, respectively, compared with IFNbeta alone at 48 weeks.	teriflunomide	74-87	interferon beta 1	Homo sapiens	226-233	
28321835-5	2017	Seventy-six percentages of patients shifted to teriflunomide from treatment with interferon-beta.	teriflunomide	47-60	interferon beta 1	Homo sapiens	81-96	
25182864-2	2014	Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS.	teriflunomide	260-273	interferon beta 1	Homo sapiens	69-77	
24759080-4	2014	RECENT FINDINGS: Recent large placebo-controlled trials in relapsing-remitting multiple sclerosis have shown efficacy of new oral disease-modifying drugs, teriflunomide and dimethyl fumarate, with similar or better efficacy than the injectable disease-modifying drugs, IFN-beta and glatiramer acetate.	teriflunomide	155-168	interferon beta 1	Homo sapiens	269-277